+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

14 May 2019
Pharma

Visiongain has launched a new pharma report Medical Devices Leader Series : In Vitro Diagnostics (IVD) Companies Market Report : Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies.

The global in vitro diagnostics (IVD) market is estimated to have reached $69.2bn in 2018. In 2018, Visiongain notes that Big Pharma companies, namely Roche, Danaher and Siemens dominated the sector accounting for 42.4% of the global IVD market with combined revenue of $29.3bn.

The lead analyst of the report commented "In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions. This has been done primarily in response to increased competition to maintain or increase market share, and to solidify a company’s position in the market. Small innovative companies are providing new technologies which feed into the development of products by leading players. Such companies represent potential acquisition targets for corporations seeking opportunities."

Leading companies featured in the report include Abbott Laboratories, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Danaher Corporation, Laboratory Corporation of America (LabCorp), QIAGEN, Roche, Siemens AG, Sysmex Corporation, Thermo Fisher Scientific and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read